XORTX Therapeutics shares rise 28.84% after-hours after providing overnight update on acquisition of renal anti-fibrotic therapeutic program.

XORTX Therapeutics surged 28.84% in after-hours trading following an overnight update disclosing the acquisition of a renal anti-fibrotic therapeutic program. The move reflects investor optimism about the expansion of the company’s pipeline in kidney disease treatments, a high-growth therapeutic area. The acquisition, though details remain unspecified, signals strategic progress in diversifying its drug development focus, aligning with positive market sentiment for biotech firms advancing novel therapies.